Oncolys Biopharma, Yale University Conclude Licensing Agreement in AIDS Drug Development.Tokyo, Japan, June 28, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Oncolys Biopharma announced on June 27 that it has signed a licensing agreement with Yale University for 4'-ethynylstavudine (Ed4T), a new compound for the treatment of HIV-1. Under the agreement, Oncolys Biopharma will receive an exclusive license to develop and commercialize Ed4T from Yale University. Ed4T, which was developed by Yale University, Kagoshima University and Showa University, is a nucleoside reverse transcriptase inhibitor Noun 1. nucleoside reverse transcriptase inhibitor - an antiviral drug used against HIV; is incorporated into the DNA of the virus and stops the building process; results in incomplete DNA that cannot create a new virus; often used in combination with other drugs with enhanced anti-HIV-1 activity. Going forward, Oncolys Biopharma plans to conduct preclinical trials and begin phase I and II clinical trials that target HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome patients with resistance to HAART HAART highly active antiretroviral therapy. HAART Highly active antiretroviral therapy, triple combination therapy AIDS The concurrent administration of 2 nucleoside reverse transcriptase inhibitors–eg, AZT and 3TC, and a protease (Highly Active Anti-Retroviral Therapy) by 2008. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion